Globo-Hs TACA character allows for its utilization as an anticancer vaccine, inducing antibody response against the epitope. The resulting humoral immunity could enable the selective eradication of Globo H-presenting tumors. The Taiwanese biopharma company OBI Pharma, Inc., was first to develop Adagloxad Simolenin (OBI-822), a Globo H hexasaccharide conjugated with the immunostimulatory carrier protein KLH. The Phase III GLORIA study is underway evaluating the carbohydrate-based immunogens effects in high risk triple-negative breast cancer (TNBC) patients with an estimated completion date in 2027.
Alternative vaccine conjugates have been developed which avoid issues associated with the protein carrier KLH by substituting it with a lipid or carbohydrate-based carrier. Examples include the use of lipid A derivatives or entirely carbohydrate vaccine conjugates such as Globo H-PS A1